Literature DB >> 8494373

Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells.

K Nagata1, H Satoh, T Iwahi, T Shimoyama, T Tamura.   

Abstract

The gastric proton pump inhibitor lansoprazole, its active analog AG-2000, and omeprazole dose dependently inhibited urease activity extracted with distilled water from Helicobacter pylori cells; the 50% inhibitory concentrations were between 3.6 and 9.5 microM, which were more potent than those of urease inhibitors, such as acetohydroxamic acid, hydroxyurea, and thiourea. These compounds also inhibited urease activity in intact cells of H. pylori and Helicobacter mustelae but did not inhibit ureases from other bacteria, such as Proteus vulgaris, Proteus mirabilis, and Providencia rettgeri. The mechanism of urease inhibition was considered to be blockage of the SH groups of H. pylori urease, since SH residues in the enzyme decreased after preincubation with lansoprazole and glutathione or dithiothreitol completely abolished the inhibitory action. The SH-blocking reagents N-ethylmaleimide and idoacetamide were also examined for their inhibition of the urease activity; their 50% inhibitory concentrations were 100- to 1,000-fold higher than those of lansoprazole. These results suggest that lansoprazole and omeprazole can potently and selectively inhibit H. pylori urease and that inhibition may be related to earlier findings indicating that these compounds have selective activity against HP growth.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8494373      PMCID: PMC187756          DOI: 10.1128/AAC.37.4.769

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  38 in total

1.  Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate.

Authors:  C A McNulty; J C Gearty; B Crump; M Davis; I A Donovan; V Melikian; D M Lister; R Wise
Journal:  Br Med J (Clin Res Ed)       Date:  1986-09-13

2.  The mechanism of action of the gastric acid secretion inhibitor omeprazole.

Authors:  P Lindberg; P Nordberg; T Alminger; A Brändström; B Wallmark
Journal:  J Med Chem       Date:  1986-08       Impact factor: 7.446

3.  Campylobacter pyloridis and gastritis.

Authors:  B J Marshall
Journal:  J Infect Dis       Date:  1986-04       Impact factor: 5.226

4.  Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration.

Authors:  B J Marshall; J R Warren
Journal:  Lancet       Date:  1984-06-16       Impact factor: 79.321

5.  Treatment failure of ofloxacin in Campylobacter pylori infection.

Authors:  Y Glupczynski; M Labbe; A Burette; M Delmee; V Avesani; C Bruck
Journal:  Lancet       Date:  1987-05-09       Impact factor: 79.321

6.  In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylori).

Authors:  D L Van Caekenberghe; J Breyssens
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

7.  Construction of isogenic urease-negative mutants of Helicobacter pylori by allelic exchange.

Authors:  R L Ferrero; V Cussac; P Courcoux; A Labigne
Journal:  J Bacteriol       Date:  1992-07       Impact factor: 3.490

8.  Localization of omeprazole and metabolites in the mouse.

Authors:  H F Helander; C H Ramsay; C G Regårdh
Journal:  Scand J Gastroenterol Suppl       Date:  1985

9.  Campylobacter pyloridis, urease, hydrogen ion back diffusion, and gastric ulcers.

Authors:  S L Hazell; A Lee
Journal:  Lancet       Date:  1986-07-05       Impact factor: 79.321

10.  Characterization of urease from Campylobacter pylori.

Authors:  H L Mobley; M J Cortesia; L E Rosenthal; B D Jones
Journal:  J Clin Microbiol       Date:  1988-05       Impact factor: 5.948

View more
  29 in total

1.  Basis for the selective antibacterial activity in vitro of proton pump inhibitors against Helicobacter spp.

Authors:  J E Sjøstrøm; T Kühler; H Larsson
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Real-world Helicobacter pylori diagnosis in patients referred for esophagoduodenoscopy: The gap between guidelines and clinical practice.

Authors:  Dor Shirin; Shay Matalon; Benjamin Avidan; Efrat Broide; Haim Shirin
Journal:  United European Gastroenterol J       Date:  2016-01-08       Impact factor: 4.623

Review 3.  Recurrence of Helicobacter pylori infection after successful eradication: nature and possible causes.

Authors:  H X Xia; N J Talley; C T Keane; C A O'Morain
Journal:  Dig Dis Sci       Date:  1997-09       Impact factor: 3.199

4.  Inhibitory activities of lansoprazole against respiration in Helicobacter pylori.

Authors:  K Nagata; N Sone; T Tamura
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

Review 5.  Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

Review 6.  Helicobacter pylori: the place of the new macrolides in the eradication of the bacteria in peptic ulcer disease.

Authors:  A Burette; Y Glupczynski
Journal:  Infection       Date:  1995       Impact factor: 3.553

Review 7.  Optimizing acid suppression for treatment of acid-related diseases.

Authors:  R H Hunt; C Cederberg; J Dent; F Halter; C Howden; I N Marks; S Rune; R P Walt
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

8.  A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobacter pylori.

Authors:  M Hirai; T Azuma; S Ito; T Kato; Y Kohli
Journal:  J Gastroenterol       Date:  1995-08       Impact factor: 7.527

9.  In vitro antibacterial activity of omeprazole and its selectivity for Helicobacter spp. are dependent on incubation conditions.

Authors:  J E Sjöström; J Fryklund; T Kühler; H Larsson
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

10.  Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole.

Authors:  R P Logan; M M Walker; J J Misiewicz; P A Gummett; Q N Karim; J H Baron
Journal:  Gut       Date:  1995-01       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.